Scientists have developed a tool made from a modified glue gun that can 3D print bone grafts directly onto fractures and defects during surgery.
An ultrasound device that can precisely stimulate areas deep in the brain without surgery has been developed by researchers from UCL and the University of Oxford, opening up new possibilities for neurological research and treatment of disorders such as Parkinson’s disease.
In the quest to address infertility, Cornell researchers have developed a groundbreaking device that could simplify and automate oocyte cumulus removal, a critical step in assisted reproductive technologies.
When hospitalized patients struggle to breathe, doctors typically reach for their stethoscopes, but results from a Rutgers and RWJBarnabas Health clinical study in JAMA Network Open suggest they should diagnose the problem with portable ultrasounds instead.
The company raised $250 million in July to expand its manufacturing capabilities and establish multiple teams to support the launch.
OKLAHOMA CITY, Sept. 4, 2025 /PRNewswire/ — Biozen, LLC a digital health innovator integrating advanced biosensors with proprietary algorithms, will present its cuffless blood pressure technology at the American Heart Association (AHA) Hypertension Scientific Sessions on Sept. 5 at 9:00 a.m. in Baltimore, Maryland (Poster Session 2, Poster #FR443).
DENVER, Sept. 4, 2025 /PRNewswire/ — Ultrasound AI™, Inc., a pioneer in artificial intelligence for medical imaging, today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 12,369,883, “Artificial Intelligence System for Determining Clinical Values through Medical Imaging.” The patent protects the company’s proprietary system for determining current or future clinical or laboratory values directly from non-invasive medical images such as ultrasound.
Ophthalmic device company BVI Medical unveiled its new Virtuoso phaco-vitrectomy surgical platform.
Ypsomed announced that the FDA granted 510(k) clearance for SmartPilot, a digital connectivity add-on for its Ypsomate autoinjectors.
Roche announced today that it received CE mark approval for its port delivery platform containing its Susvimo therapeutic.